Advertisement
Advertisement
MLTX
MoonLake Immunotherapeutics Class A Ordinary Shares
15.52
USDSponsored
+0.75
+5.04%
Feb 06, 15:59 UTC -5
Closed
After-Market
15.60
+0.08
+0.55%
MLTX Earnings Reports
Positive Surprise Ratio
MLTX beat 8 of 14 last estimates.
57%
Next Report
Date of Next Report
Feb 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$1.00
Implied change from Q3 25 (Revenue/ EPS)
--
/-9.09%
Implied change from Q4 24 (Revenue/ EPS)
--
/+38.89%
MoonLake Immunotherapeutics Class A Ordinary Shares earnings per share and revenue
On Nov 05, 2025, MLTX reported earnings of -1.10 USD per share (EPS) for Q3 25, missing the estimate of -0.89 USD, resulting in a -22.75% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.54% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analysts forecast an EPS of -1.00 USD, with revenue projected to reach -- USD, implying an decrease of -9.09% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were MoonLake Immunotherapeutics Class A Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, MoonLake Immunotherapeutics Class A Ordinary Shares reported EPS of -$1.10, missing estimates by -22.75%, and revenue of $0.00, 0% as expectations.
How did the market react to MoonLake Immunotherapeutics Class A Ordinary Shares's Q3 2025 earnings?
The stock price moved up 4.54%, changed from $10.13 before the earnings release to $10.59 the day after.
When is MoonLake Immunotherapeutics Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Feb 26, 2026.
What are the forecasts for MoonLake Immunotherapeutics Class A Ordinary Shares's next earnings report?
Based on 18
analysts, MoonLake Immunotherapeutics Class A Ordinary Shares is expected to report EPS of -$1.00 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement